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1.1. Physical Measurements 
 
 Melting points were determined on a Mel-Temp capillary melting points apparatus, 
model 1001 and are uncorrected. Elemental (C, H, N, S) analysis of the samples was carried out 
by standard micromethods in the Center for Instrumental Analysis, Faculty of Chemistry, 
Belgrade. IR spectra were recorded on a Perkin Elmer Spectrum One FT-IR spectrometer with a 
KBr disc. All 1H and 13C NMR spectra were recorded on a Varian Gemini 200 spectrometer and 
Bruker Avance III 500 MHz spectrometer. The full assignments of all reported 1H NMR signals 
were made by use of 1D and 2D NMR experiments such as COSY, HSQC and HMBC 
heteronuclear correlation techniques. 
 
1.2. Spectral data for the synthesized compounds 
 
1.2.1. 1a: 0.37 g (75 %); light yellow powder; Mp=231–232°C. 1H NMR (200 MHz, DMSO-d6): 
δ = 1.36 (t, 3H, J=7.2 Hz, CH3), 4.32 (q, 2H, J=7.2 Hz, CH2), 7.49 (m, 3H, Ar–H), 7.67 (dd, 2H, 
J=7.8 and 1.6 Hz, Ar–H), 8.38 (s, 1H, Pz–H), 8.45 (s, 1H, CH=N), 11.62 (s, 1H, NH–C–O), 
12.05 (s, 1H, OH), 13.36 (s, 1H, NH, Pz). 13C NMR (50 MHz, DMSO-d6): δ =14.38, 60.36, 
100.84, 101.09, 127.21, 128.94, 129.06, 132.37, 134.26, 142.55, 147.81, 148.78, 162.44, 168.62. 
IR (KBr disc, cm-1): 3422, 3314, 3110, 1710, 1679, 1626, 1574, 1295, 771. Anal. Calcd. for 
C16H15N5O3 (325.33 g/mol): C, 59.07; H, 4.65; N, 21.53; Found: C, 59.48; H, 4.75; N, 21.64. 
 
1.2.2. 1b: 0.27 g (56 %); light yellow powder; Mp=203–204°C. 1H NMR (200 MHz, DMSO-d6): 
δ = 6.63 (dd, 1H, J=3.2 and 1.8 Hz, Fur–H), 6.83 (d, 1H, J=3.2 Hz, Fur–H), 6.86 (d, 1H, J=3.2 
Hz, Pz–H), 7.49 (m, 3H, Ar–H), 7.71 (dd, 2H, J=7.8 and 1.6 Hz, Ar–H),  7.80 (d, 1H, J=1.8 Hz, 
Fur–H), 8.45 (s, 1H, –CH=N), 11.59 (s, 1H, NH–C–O), 11.90 (bs, 1H, OH), 13.23 (s, 1H, NH, 
Pz). 13C NMR (50 MHz, DMSO-d6): δ = 90.95, 99.03, 107.55, 112.03, 127.34, 128.72, 128.95, 
132.62, 135.64, 143.45, 144.37, 145.66, 148.73, 148.98, 168.77. IR (KBr disc, cm-1): 3429, 
3199, 3153, 1659, 1612, 1489, 1300, 1278, 955, 781. Anal. Calcd. for C17H13N5O2 (319.32 
g/mol): C, 63.94; H, 4.10; N, 21.93; Found: C, 64.19; H, 4.16; N, 22.07. 
 
1.2.3. 1c: 0.21 g (52 %); light yellow powder; Mp=191–192°C (dec). 1H NMR (200 MHz, 
DMSO-d6): δ = 2.22 (s, 3H, CH3), 6.25 (s, 1H, Pz–H), 7.48 (m, 3H, Ar–H), 7.68 (dd, 2H, J=7.8 
and 1.6 Hz, Ar–H), 8.36 (s, 1H, –CH=N), 10.95 (bs, 1H, OH), 11.55 (s, 1H, NH–C–O), 12.39 (s, 
1H, NH, Pz). 13C NMR (50 MHz, DMSO-d6): δ = 10.88, 93.35, 98.56, 127.28, 128.68, 128.96, 
132.70, 140.76, 145.74, 148.31, 148.66, 168.76. IR (KBr disc, cm-1): 3421, 3190, 3152, 1665, 
1622, 1579, 1487, 1404, 1302, 753. Anal. Calcd. for C14H13N5O (267.29 g/mol): C, 62.91; H, 
4.90; N, 26.20; Found: C, 63.24; H, 4.99; N, 26.44.  
 
1.2.4. 1d: 0.20 g (53 %); yellow powder; Mp=207–208°C (dec). 1H NMR (200 MHz, DMSO-
d6): δ =  6.50 (d, 1H, J=2.4 Hz, Pz–H), 7.45 (m, 3H, Ar–H), 7.69 (dd, 2H, J=7.8 and 1.6 Hz, Ar–
H), 7.74 (d, 1H, J=2.4 Hz, Pz–H), 8.43 (s, 1H, –CH=N), 11.40 (bs, 1H, OH), 11.57 (s, 1H, NH–
C–O), 12.69 (bs, 1H, NH, Pz). 13C NMR (50 MHz, DMSO-d6): δ = 94.26, 98.71, 127.31, 128.71, 
128.96, 130.97, 132.69, 145.67, 148.26, 148.74, 168.77.  IR (KBr disc, cm-1): 3415, 3306, 3189, 
1673, 1614, 1596, 1399, 1385, 742. Anal. Calcd. for C13H11N5O (253.26 g/mol): C, 61.65; H, 
4.38; N, 27.65; Found: C, 61.95; H, 4.43; N, 27.81. 
 
1.2.5. 1e: 0.38 g (76 %); light yellow powder; Mp=210–211°C (dec). 1H NMR (200 MHz, 
DMSO-d6): δ = 6.99 (s, 1H, Pz–H), 7.46 (m, 6H, Ar–H), 7.73 (m, 4H, Ar–H), 8.47 (s, 1H, –
CH=N), 11.58 (bs, 1H, OH), 11.63 (s, 1H, NH–C–O),  13.21 (bs, 1H, NH, Pz). 13C NMR (50 
MHz, DMSO-d6): δ = 91.70, 98.97, 124.95, 125.35, 127.39, 128.80, 128.83, 129.04, 129.26, 
132.68, 144.22, 145.72, 148.80, 149.16, 168.88. IR (KBr disc, cm-1): 3427, 3169, 1658, 1609, 
1586, 1487, 1405, 1299, 1280, 954, 783. Anal. Calcd. for C19H15N5O (329.36 g/mol): C, 69.29; 
H, 4.59; N, 21.26; Found: C, 69.30; H, 4.59; N, 21.44.  
 
1.2.6. 1f ∙ H2O: 0.40 g (76 %); light yellow powder; Mp=137–138°C (dec). 1H NMR (500 MHz, 
DMSO-d6): δ = 3.08, (dd, 1H, J = 14.0 and 8.5 Hz, CH–CH2), 3.29, (dd, 1H, J = 14.0 and 4.5 Hz, 
CH–CH2), 4.71, (dd 1H, J = 8.5 and 4.5 Hz, CH–COO), 7.24–7.38 (m, 10H, Ar–H), 7.65 (s, 1H, 
–CH=N), 10.09 (bs, 1H, OH), 11.25 (s, 1H, NH–C–O), 12.79 (bs, 1H, COOH). 13C NMR (125 
MHz, DMSO-d6): δ = 38.81, 61.43, 96.42, 126.91, 126.94, 128.24, 128.55, 128.63, 129.72, 
132.75, 136.19,  148.25, 152.89, 168.61, 171.57. IR (KBr disc, cm-1): 3413, 3352, 3152, 1710, 
1659, 1590, 1507, 1400, 1306, 1283, 771. Anal. Calcd. for C19H19N3O4 (353.38 g/mol): C, 64.58; 
H, 5.42; N, 11.89;  Found: C, 64.28; H, 5.60; N, 11.82. 
 
1.2.7. 1g ∙ H2O: 0.32 g (62 %); yellow powder; Mp=107–108°C (dec). 1H NMR (500 MHz, 
DMSO-d6): δ = 2.05, (s, 3H, CH3); 2.07, (m, 1H, CH–CH2); 2.15, (m, 1H, CH–CH2); 2.50, (m, 
2H,  S–CH2); 4.46, (dd, 1H, J = 8.0 and 5.0 Hz, CH–COO), 7.39 (t, 1H, J=7.0 Hz, Ar–H), 7.44 
(t, 2H, J=7.0 Hz, Ar–H), 7.61 (dd, 2H, J=7.0 and 1.5 Hz, Ar–H), 8.10 (s, 1H, –CH=N), 10.23 
(bs, 1H, OH), 11.30 (s, 1H, NH–C–O), 12.85 (bs, 1H, COOH). 13C NMR (125 MHz, DMSO-d6): 
δ = 14.54, 29.07, 32.20, 59.75, 96.68, 127.00, 128.25, 128.66, 132.91, 148.18, 153.33, 168.73, 
172.02. IR (KBr disc, cm-1): 3420, 3170, 1720, 1662, 1606, 1505, 1400, 1280, 769. Anal. Calcd. 
for C15H19N3O4S (337.40 g/mol): C, 53.40; H, 5.68; N, 12.45; S, 9.50; Found: C, 53.27; H, 5.88; 
N, 12.41; S, 9.84. 
 
1.2.8. 1h: 0.20 g (44 %); light yellow powder; Mp=164–165°C (dec). 1H NMR (500 MHz, 
DMSO-d6): δ = 2.11, (s, 3H, CH3), 3.03, (dd, 1H, J = 14.0 and 7.0 Hz, CH–CH2), 3.08, (dd, 1H, J 
= 14.0 and 4.5 Hz, CH–CH2), 4.66, (dd 1H, J = 7.0 and 4.5 Hz, CH–COO), 7.39 (t, 1H, J=7.0 
Hz, Ar–H), 7.45 (t, 2H, J=7.0 Hz, Ar–H), 7.61 (d, 2H, J=7.0 Hz, Ar–H), 8.14 (s, 1H, –CH=N), 
10.22 (bs, 1H, OH), 11.32 (s, 1H, NH–C–O), 12.84 (bs, 1H, COOH). 13C NMR (125 MHz, 
DMSO-d6): δ = 15.43, 37.06, 60.00, 96.73, 126.99, 128.32, 128.72, 132.89, 148.26, 153.43, 
168.74, 171.02. IR (KBr disc, cm-1): 3413, 3256, 1731, 1662, 1605, 1506, 1400, 1304, 771. Anal. 
Calcd. for C14H15N3O3S (305.36 g/mol): C, 55.07; H, 4.95; N, 13.76; S, 10.50;  Found: C, 54.85; 
H, 5.14; N, 13.62; S, 10.27. 
 
1.2.9. 1i: 0.18 g (44 %); yellow powder; Mp=178–179°C (dec). 1H NMR (500 MHz, DMSO-d6): 
δ = 3.79, (dd, 1H, J = 11.0 and 3.5 Hz, CH–CH2), 3.84, (dd, 1H, J = 11.0 and 4.5 Hz, CH–CH2), 
4.47, (m, 1H, CH–COO), 5.45, (bs, 1H, CH2–OH), 7.39 (t, 1H, J=7.0 Hz, Ar–H), 7.44 (t, 2H, 
J=7.0 Hz, Ar–H), 7.60 (d, 2H, J=7.0 Hz, Ar–H), 8.10 (s, 1H, –CH=N), 10.27 (bs, 1H, OH), 
11.27 (s, 1H, NH–C–O), 12.89 (bs, 1H, COOH). 13C NMR (125 MHz, DMSO-d6): δ = 62.24, 
62.31, 96.58, 126.96, 128.22, 128.72, 132.98, 148.19, 153.61, 168.69, 170.85. IR (KBr disc, cm-
1): 3421, 3226, 1715, 1661, 1616, 1603, 1400, 1255, 772. Anal. Calcd. for C13H13N3O4 (275.26 
g/mol): C, 56.72; H, 4.76; N, 15.27; Found: C, 57.01; H, 4.67; N, 15.10. 
 
1.2.10. 1j ∙ H2O: 0.42 g (75 %); yellow powder; Mp=155–156°C (dec). 1H NMR (500 MHz, 
DMSO-d6): δ = 2.92, (dd, 1H, J = 13.5 and 9.0 Hz, CH–CH2), 3.17, (dd, 1H, J = 13.5 and 4.5 Hz, 
CH–CH2), 4.60, (dd 1H, J = 9.0 and 4.5 Hz, CH–COO), 6.72 (d, 2H, J=8.5 Hz, Ar–H), 7.02 (d, 
2H, J=8.5 Hz, Ar–H), 7.41 (m, 3H, Ar–H), 7.53 (m, 2H, Ar–H), 7.55 (s, 1H, –CH=N), 9.38 (bs, 
1H, Ar–OH), 10.09 (bs, 1H, OH), 11.22 (s, 1H, NH–C–O), 12.86 (bs, 1H, COOH). 13C NMR 
(125 MHz, DMSO-d6): δ = 38.45, 61.54, 96.27, 115.32, 126.91, 128.17, 128.63, 128.73, 130.75, 
132.75,  148.25, 152.76, 156.44, 168.57, 171.64. IR (KBr disc, cm-1): 3401, 3296, 3204, 1735, 
1656, 1609, 1591, 1514, 1331, 1284, 776. Anal. Calcd. for C19H19N3O5 (369.38 g/mol): C, 61.78; 
H, 5.18; N, 11.38;  Found: C, 61.48; H, 5.28; N, 11.16. 
 
1.2.11. 1k: 0.21 g (43 %); light yellow powder; Mp=232–233°C (dec). 1H NMR (500 MHz, 
DMSO-d6): δ = 3.04, (dd, 1H, J = 15.0 and 8.0 Hz, CH–CH2), 3.18, (dd, 1H, J = 15.0 and 4.0 Hz, 
CH–CH2), 4.63, (dd 1H, J = 8.0 and 4.0 Hz, CH–COO), 6.95, (s, 1H, His–H), 7.38, (m, 1H, NH, 
His), 7.43 (m, 5H, Ar–H), 7.70 (s, 1H, –CH=N), 7.78 (s, 1H, His–H),  10.17 (bs, 1H, OH), 11.21 
(s, 1H, NH–C–O), 12.89 (bs, 1H, COOH). 13C NMR (125 MHz, DMSO-d6): δ =  31.14, 60.24, 
96.22, 116.56, 126.85, 128.13,  128.62, 128.96,  132.86, 135.11, 148.15, 152.78, 168.51, 171.68. 
IR (KBr disc, cm-1): 3235, 3151, 1711, 1670, 1635, 1591, 1350, 1300, 1273, 775. Anal. Calcd. 
for C16H15N5O3 (325.33 g/mol): C, 59.07; H, 4.65; N, 21.53;  Found: C, 59.23; H, 4.55; N, 21.44. 
 
1.2.12. 1l ∙ H2O: 0.49 g (84 %); light yellow powder; Mp=163–164°C (dec). 1H NMR (500 
MHz, DMSO-d6): δ = 3.19, (dd, 1H, J = 14.5 and 9.0 Hz, CH–CH2), 3.43, (dd, 1H, J = 14.5 and 
4.0 Hz, CH–CH2), 4.66, (dd 1H, J = 9.0 and 4.0 Hz, CH–COO), 7.00 (t, 1H, J = 7.0 Hz, Ar–H), 
7.13 (m, 3H, Ar–H), 7.20 (d, 1H, J = 2.0 Hz, Trp–H), 7.30 (m, 3H, Ar–H), 7.41 (s, 1H, –CH=N), 
7.43 (m, 1H, Ar–H), 7.58 (d, 1H, J = 8.0 Hz, Ar–H), 10.22 (bs, 1H, OH), 11.05 (d, 1H, J = 2.0 
Hz, N–H, Trp), 11.20 (s, 1H, NH–C–O), 12.77 (bs, 1H, COOH). 13C NMR (125 MHz, DMSO-
d6): δ = 29.77, 60.83, 96.04, 108.45, 111.56, 118.41, 118.73, 121.23, 124.79, 126.71, 126.90, 
128.00, 128.56, 132.77, 136.33,  148.14, 152.48, 168.55, 172.04. IR (KBr disc, cm-1): 3399, 
3220, 1723, 1657, 1595, 1503, 1340, 1284, 744. Anal. Calcd. for C21H20N4O4 (392.41 g/mol): C, 
64.28; H, 5.14; N, 14.28;  Found: C, 64.17; H, 5.08; N, 14.44. 
 
1.2.13. 1m: 0.45 g (74 %); yellow powder; Mp=244–245°C (dec). 1H NMR (200 MHz, DMSO-
d6): δ = 1.37 (t, 3H, J=7.2 Hz, CH3), 4.34 (q, 2H, J=7.2 Hz, CH2), 7.21 (t, 1H, J=7.4 Hz, Ar–H), 
7.53 (m, 5H, Ar–H), 7.79 (m, 2H, Ar–H), 8.07 (d, 2H, J=7.8 Hz, Ar–H), 8.41 (d, 1H, J=1.8 Hz, 
Pz–H), 8.54 (d, 1H, J=13.0 Hz, =CH–N), 12.14 (d, 1H, J=13.0 Hz, NH), 13.44 (s, 1H, NH, Pz). 
13C NMR (50 MHz, DMSO-d6): δ = 14.37, 60.45, 101.17, 101.27, 118.38, 124.60, 127.67, 
128.99, 129.16, 129.59, 131.43, 134.10, 138.84, 143.91, 147.62, 149.66, 162.58, 165.19. IR 
(KBr disc, cm-1): 3421, 3377, 3234, 3156, 1672, 1614, 1595, 1490, 1340, 1283, 776. Anal. 
Calcd. for C22H19N5O3 (401.42 g/mol): C, 65.83; H, 4.77; N, 17.45; Found: C, 65.98; H, 4.82; N, 
17.54. 
 
1.2.14. 1n: 0.42 g (71 %); light yellow powder; Mp=247–248°C (dec). 1H NMR (200 MHz, 
DMSO-d6): δ = 6.65 (dd, 1H, J=3.6 and 1.8 Hz, Fur–H), 6.85 (d, 1H, J=3.6 Hz, Fur–H), 6.87 (d, 
1H, J=3.2 Hz, Pz–H), 7.21 (t, 1H, J=7.4 Hz, Ar–H), 7.52 (m, 5H, Ar–H), 7.81 (d, 1H, J=1.8 Hz, 
Fur–H), 7.83 (m, 2H, Ar–H), 8.10 (d, 2H, J=7.8 Hz, Ar–H), 8.54 (s, 1H, –CH=N), 11.94 (bs, 1H, 
OH), 13.31 (s, 1H, NH, Pz). 13C NMR (50 MHz, DMSO-d6): δ = 91.53, 99.54, 107.62, 112.02, 
118.45, 124.55, 127.84, 128.99, 129.07,  129.39, 131.69,  135.57, 138.99, 143.49, 144.23, 
146.58, 148.74, 149.71, 165.26. IR (KBr disc, cm-1): 3436, 3250, 3117, 1677, 1620, 1485, 1399,  
1327, 752. Anal. Calcd. for C23H17N5O2 (395.42 g/mol): C, 69.86; H, 4.33; N, 17.71; Found: C, 
70.01; H, 4.40; N, 17.77. 
 
1.2.15. 1o: 0.31 g (61 %); light yellow crystals ; Mp=221–222°C (dec). 1H NMR (200 MHz, 
DMSO-d6): δ = 2.23 (s, 3H, CH3), 6.29 (s, 1H, Pz–H), 7.19 (t, 1H, J=7.4 Hz, Ar–H), 7.50 (m, 
5H, Ar–H), 7.79 (m, 2H, Ar–H), 8.09 (d, 2H, J=7.8 Hz, Ar–H), 8.45 (s, 1H, –CH=N), 11.83 (bs, 
1H, OH), 12.47 (s, 1H, NH, Pz). 13C NMR (50 MHz, DMSO-d6): δ = 10.84, 93.95, 99.09, 
118.42, 124.49, 127.77, 128.97, 129.07, 129.36, 131.77,  139.05, 140.78, 146.35, 148.05, 149.65, 
165.28. IR (KBr disc, cm-1): 3420, 3269, 1680, 1617, 1602, 1522, 1482, 1402, 1331, 754. Anal. 
Calcd. for C20H17N5O (343.39 g/mol): C, 69.96; H, 4.99; N, 20.39; Found: C, 70.14; H, 5.03; N, 
20.65. 
 
1.2.16. 1p: 0.30 g (61 %); light yellow powder; Mp=214–215°C (dec). 1H NMR (200 MHz, 
DMSO-d6): δ = 6.55 (s, 1H, Pz–H), 7.19 (t, 1H, J=7.4 Hz, Ar–H), 7.51 (m, 5H, Ar–H), 7.79 (s, 
1H, Pz–H), 7.80 (m, 2H, Ar–H), 8.09 (d, 2H, J=7.8 Hz, Ar–H), 8.52 (s, 1H, –CH=N), 11.94 (bs, 
1H, OH), 12.79 (s, 1H, NH, Pz). 13C NMR (50 MHz, DMSO-d6): δ = 94.88, 99.24, 118.43, 
124.51, 127.80, 128.99, 129.08, 129.37, 130.96,  131.76, 139.05, 146.59, 148.03, 149.71, 165.28.  
IR (KBr disc, cm-1): 3435, 3232, 1656, 1629, 1597, 1481, 1401, 1344, 756. Anal. Calcd. for 
C19H15N5O (329.36 g/mol): C, 69.29; H, 4.59; N, 21.26; Found: C, 69.55; H, 4.63; N, 21.33. 
1.2.17. 1q: 0.44 g (73 %); light yellow powder; Mp=287–288°C (dec). 1H NMR (200 MHz, 
DMSO-d6): δ = 7.02 (s, 1H, Pz–H), 7.21 (t, 1H, J=7.4 Hz, Ar–H), 7.47 (m, 8H, Ar–H), 7.40 (d, 
2H,  J=7.0 Hz, Ar–H), 7.83 (m, 2H, Ar–H), 8.09 (d, 2H, J=7.8 Hz, Ar–H), 8.55 (s, 1H, –CH=N), 
11.37 (bs, 1H, OH), 13.29 (s, 1H, NH, Pz). 13C NMR (50 MHz, DMSO-d6): δ = 92.25, 99.44, 
118.52, 124.62, 125.35, 127.85, 128.86, 129.04, 129.13, 129.19, 129.25, 129.45, 131.73 139.02, 
144.16, 146.64, 148.93, 149.71, 165.35. IR (KBr disc, cm-1): 3434, 3212, 1672, 1623, 1598, 
1488, 1481, 1403, 1333, 755. Anal. Calcd. for C25H19N5O (405.46 g/mol): C, 74.06; H, 4.72; N, 
17.27; Found: C, 74.19; H, 4.81; N, 17.44.  
 
1.2.18. 1r and 1s: 0.55 g for 1r and 0.43 g for 1s (89 % for 1r and 69 % for 1s); yellow powder; 
Mp=235–236°C (dec). 1H NMR (500 MHz, DMSO-d6): δ =  3.15, (dd, 1H, J = 14.0 and 8.5 Hz, 
CH–CH2), 3.34, (dd, 1H, J = 14.0 and 4.5 Hz, CH–CH2), 4.83, (ddd, 1H, J = 9.0, 8.5 and 4.5 Hz, 
CH–COO), 7.16 (t, 1H, J=7.5 Hz, Ar–H), 7.28 (m, 3H, Ar–H), 7.35 (t, 2H, J=7.5 Hz, Ar–H), 
7.40–7.45, (m, 7H, Ar–H), 7.77, (d, 1H,  J = 13.5 Hz, =CH–N), 8.04, (d, 2H, J=7.5 Hz, Ar–H), 
10.21 (dd, 1H, J = 13.5 and 9.0 Hz,  NH), 13.63 (bs, 1H, COOH). 13C NMR (125 MHz, DMSO-
d6): δ =  38.73, 61.50, 96.92, 118.08, 124.05, 126.98, 127.34, 128.56, 128.74, 128.82, 128.94, 
129.71,  131.69, 135.96, 139.09,  149.08, 153.97, 165.29, 171.29. IR (KBr disc, cm-1): 3445, 
1731, 1656, 1597, 1574,1494, 1353, 1258, 1188, 758, 698. Anal. Calcd. for C25H21N3O3 (411.46 
g/mol): C, 72.98; H, 5.14; N, 10.21;  Found: C, 72.96; H, 5.18; N, 10.29. 
 
1.2.19. 1t: 0.43 g (73 %); yellow powder; Mp=167–168°C (dec). 1H NMR (500 MHz, DMSO-
d6): δ = 2.06, (s, 3H, CH3); 2.18, (m, 2H, CH–CH2); 2.54, (m, 2H,  S–CH2);  4.62, (ddd, 1H, J = 
9.0, 8.0 and 3.5 Hz, CH–COO), 7.17 (t, 1H, J=7.5 Hz, Ar–H), 7.43 (t, 2H, J=7.5 Hz, Ar–H), 
7.48–7.53, (m, 3H, Ar–H), 7.75 (dd, 2H, J=8.0 and 1.5 Hz, Ar–H), 8.07, (d, 2H, J=8.0 Hz, Ar–
H), 8.26, (d, 1H,  J = 13.5 Hz, =CH–N), 10.31 (dd, 1H, J = 13.5 and 9.0 Hz,  NH), 13.48 (bs, 1H, 
COOH). 13C NMR (125 MHz, DMSO-d6): δ = 14.50, 29.01, 31.67, 59.75, 97.32, 118.14, 124.09, 
127.50, 128.76, 128.80, 129.01,  131.87, 139.10,  149.10, 154.62, 165.44, 171.75. IR (KBr disc, 
cm-1): 3436, 3285, 1731, 1655, 1598, 1572,1494, 1351, 1281, 758. Anal. Calcd. for C21H21N3O3S 
(395.48 g/mol): C, 63.78; H, 5.35; N, 10.63; S, 8.11;  Found: C, 64.02; H, 5.25; N, 10.79; S, 
8.26. 
 
1.2.20. 1u: 0.37 g (64 %); yellow powder; Mp=149–150°C (dec). 1H NMR (500 MHz, DMSO-
d6): δ = 2.13, (s, 3H, CH3); 3.10, (dd, 1H, J = 14.0 and 7.0 Hz, CH–CH2), 3.14, (dd, 1H, J = 14.0 
and 4.5 Hz, CH–CH2), 4.76, (m, 1H,  CH–COO), 7.17 (t, 1H, J=7.0 Hz, Ar–H), 7.43 (t, 2H, 
J=8.0 Hz, Ar–H), 7.47–7.54, (m, 3H, Ar–H), 7.74 (d, 2H, J=7.0 Hz, Ar–H), 8.07, (d, 2H, J=8.0 
Hz, Ar–H), 8.27, (d, 1H,  J = 13.5 Hz, =CH–N), 10.37 (dd, 1H, J = 13.5 and 9.0 Hz,  NH), 13.62 
(bs, 1H, COOH). 13C NMR (125 MHz, DMSO-d6): δ = 15.36, 36.82, 60.07, 97.24, 118.13, 
124.10, 127.46, 128.76, 128.85, 129.04,  131.86, 139.11,  149.11, 154.56, 165.44, 170.81. IR 
(KBr disc, cm-1): 3421, 3116, 1736, 1650, 1598, 1574,1496, 1349, 1183, 767. Anal. Calcd. for 
C20H19N3O3S (381.46 g/mol): C, 62.97; H, 5.02; N, 11.02; S, 8.41;  Found: C, 63.05; H, 4.95; N, 
10.98; S, 8.35. 
 
1.2.21. 1v: 0.32 g (61 %); yellow powder; Mp=106–107°C (dec). 1H NMR (500 MHz, DMSO-
d6): δ = 3.83, (m, 1H, CH–CH2), 3.88, (dd, 1H, J = 10.5 and 3.5 Hz, CH–CH2), 4.56, (m, 1H, 
CH–COO), 5.45, (bs, 1H, CH2–OH), 7.17 (t, 1H, J=7.5 Hz, Ar–H), 7.43 (t, 2H, J=7.5 Hz, Ar–
H), 7.48 (m, 3H, Ar–H), 7.73 (d, 2H, J=7.0 Hz, Ar–H), 8.08, (d, 2H, J=8.0 Hz, Ar–H), 8.25, (d, 
1H,  J = 13.5 Hz, =CH–N), 10.39 (dd, 1H, J = 13.5 and 8.5 Hz,  NH), 13.40 (bs, 1H, COOH). 13C 
NMR (125 MHz, DMSO-d6): δ = 62.18, 62.42, 97.14, 118.10, 124.03, 127.43, 128.76, 128.83, 
128.99,  131.96, 139.20,  149.09, 154.73, 165.45, 170.64. IR (KBr disc, cm-1): 3410, 3232, 1734, 
1657, 1598, 1495, 1348, 758. Anal. Calcd. for C19H17N3O4 (351.23 g/mol): C, 64.95; H, 4.88; N, 
11.96; Found: C, 65.25; H, 4.82; N, 11.69. 
 
1.2.22. 1w: 0.51 g (80 %); yellow powder; Mp=209–210°C (dec). 1H NMR (500 MHz, DMSO-
d6): δ =  2.99, (dd, 1H, J = 14.0 and 9.0 Hz, CH–CH2), 3.23, (dd, 1H, J = 14.0 and 4.0 Hz, CH–
CH2), 4.83, (ddd, 1H, J = 9.0, 9.0 and 4.0 Hz, CH–COO), 6.75, (d, 2H, J=8.5 Hz, Ar–H), 7.06 (d, 
2H, J=8.5 Hz, Ar–H), 7.16 (t, 1H, J=7.5 Hz, Ar–H), 7.40–7.47 (m, 7H, Ar–H), 7.66, (d, 1H,  J = 
13.0 Hz, =CH–N), 8.05, (d, 2H, J=8.0 Hz, Ar–H), 9.41 (bs, 1H, OH, Tyr), 10.19, (dd, 1H, J = 
13.0 and 9.0 Hz,  NH), 13.61 (bs, 1H, COOH). 13C NMR (125 MHz, DMSO-d6): δ =  38.28, 
61.75, 96.77, 115.37, 118.08, 124.03, 125.79, 127.36, 128.74, 128.78, 128.92, 130.82, 131.71, 
139.13,  149.14, 153.80, 156.50, 165.30, 171.40. IR (KBr disc, cm-1): 3517, 3420, 3204, 1732, 
1655, 1596, 1516, 1494, 1351, 1175, 760. Anal. Calcd. for C25H21N3O4 (427.46 g/mol): C, 70.25; 
H, 4.95; N, 9.83;  Found: C, 69.95; H, 5.01; N, 9.79; 
 
1.2.23. 1x: 0.42 g (70 %); yellow powder; Mp=214–215°C (dec). 1H NMR (500 MHz, DMSO-
d6): δ =  3.12, (dd, 1H, J = 15.0 and 8.5 Hz, CH–CH2), 3.23, (dd, 1H, J = 15.0 and 4.0 Hz, CH–
CH2), 4.73, (m, 1H, CH–COO), 7.02, (s, 1H, His–H), 7.16 (t, 1H, J=7.5 Hz, Ar–H), 7.42 (t, 2H, 
J=8.0 Hz, Ar–H), 7.46–7.52 (m, 4H; 3H, Ar–H and 1H, NH, His), 7.57, (d, 2H, J=7.0 Hz, Ar–
H), 7.86, (m, 2H,  =CH–N and 1h, His), 8.05, (d, 2H, J=8.0 Hz, Ar–H), 10.31, (m, 1H, NH), 
13.54 (bs, 1H, COOH). 13C NMR (125 MHz, DMSO-d6): δ =  30.77, 60.47, 96.83, 116.43, 
118.07, 123.97, 127.36, 128.72, 128.80, 128.91, 131.86, 132.70, 135.17, 139.18,  149.09, 153.93, 
165.27, 171.44. IR (KBr disc, cm-1): 3420, 3155, 1715, 1653, 1598, 1570,1499, 1347, 1333, 762. 
Anal. Calcd. for C22H19N5O3 (401.42 g/mol): C, 65.83; H, 4.77; N, 17.45;  Found: C, 65.52; H, 
4.80; N, 17.33; 
 
1.2.24. 1y: 0.50 g (74 %); yellow powder; Mp=234–235°C (dec). 1H NMR (500 MHz, DMSO-
d6): δ = 3.28, (dd, 1H, J = 14.5 and 8.5 Hz, CH–CH2), 3.45, (dd, 1H, J = 14.5 and 4.5 Hz, CH–
CH2), 4.79, (ddd 1H, J = 9.0, 8.5 and 4.0 Hz, CH–COO), 7.00 (t, 1H, J = 7.5 Hz, Ar–H), 7.12, (t, 
1H, J = 7.5 Hz, Ar–H), 7.16, (t, 1H, J = 7.5 Hz, Ar–H), 7.25 (m, 3H; 2H, Ar–H and 1H, Trp–H), 
7.35–7.43 (m, 6H; 5H, Ar–H and 1H, =CH–N), 7.58 (m, 2H, Ar–H), 8.04 (d, 2H, J = 7.5 Hz, 
Ar–H), 10.28 (dd, 1H, J = 13.5 and 9.0 Hz,  NH), 11.07 (s, 1H, N–H, Trp), 13.58 (bs, 1H, 
COOH). 13C NMR (125 MHz, DMSO-d6): δ = 29.37, 60.72, 96.70, 108.03, 111.56, 118.08, 
118.38, 118.74,  121.27, 124.01, 124.91,  126.84, 127.17, 128.66, 128.72, 128.79, 131.69, 
136.31, 139.13, 149.02, 153.70, 165.31, 171.74. IR (KBr disc, cm-1): 3399, 3220, 1723, 1657, 
1595, 1503, 1340, 1284, 744. Anal. Calcd. for C27H22N4O3 (450.50 g/mol): C, 71.99; H, 4.92; N, 
12.44;  Found: C, 71.77; H, 4.92; N, 12.30. 
 
1.3. Treatment of tumor cell lines 
 
 Stock solutions (10mM) of compounds were made in dimethylsulfoxide (DMSO), and 
dissolved in corresponding medium to the required working concentrations. Human breast cancer 
MDA-MB-361 and MDA-MB-453 cells were cultured as a monolayer, while were grown in a 
suspension in the complete nutrient medium, at 37ºC in humidified air atmosphere with 5% CO2. 
For the growth of MDA-MB-361 and MDA-MB-453 cells complete medium was enriched with 
1.11 g/L glucose. Then, MDA-MB-361 cells (7000 cells per well) and MDA-MB-453 cells 
(3000 cells per well), were seeded into 96-well microtiter plates. Twenty-four hours later, after 
the cell adherence, five different, double diluted, concentrations of investigated compounds were 
added to the wells, except for the control cells to which a nutrient medium only was added. 
Nutrient medium was RPMI-1640, supplemented with L-glutamine (3 mM), streptomycin (100 
lg/mL), and penicillin (100 IU/mL), 10% heat inactivated (56ºC) FBS and 25 mM Hepes, and the 
pH of the medium was adjusted to 7.2 by bicarbonate solution. The cultures were incubated for 
72 h. At the end of this incubation period, antiproliferative activity in vitro was determined by 
the MTT test1 modified by Ohno and Abe.2 Results are presented as the mean ± SD of three 
independent experiments. IC50 is used as the measure of the toxic agents action and is determined 
from the graph S(%)=f(c), as the concentration of the agent which induces decrease in cell 
survival to 50%. 
 
1.4. QSAR analysis 
 
 The set of 25 compounds synthesized in this study (Scheme 1) was used for QSAR 
(quantitative structure-activity relationships) analysis. All structures were constructed using 
Spartan software.3 Geometry optimization was performed by the AM1 semi-empirical method 
implemented in the Spartan software. Calculation of descriptors was performed using Codessa 
software (Comprehensive Descriptors for Structural and Statistical Analysis).4 A total of 450 
descriptors were calculated and divided into five groups: constitutional, topological, geometrical, 
electrostatic and quantum-chemical. The heuristic method (HM) implemented in Codessa 
software was used for the selection of the most significant descriptors for antiproliferative 
activity of investigated derivatives on MDA-MB-361 and MDA-MB-453 cancer cells. HM, as an 
advanced algorithm based on MLR, is suitable for preliminary studies of structural features 
important for activity of ligands, when mechanism of action of new compounds is not discovered 
yet. The advantage of HM is based on its unique strategy of selecting descriptors on the basis of 
their statistical significance: a) first of all, all descriptors are checked to ensure that values of 
each descriptor are available for each structure, otherwise descriptors for which values are not 
available in data set are discarded; b) descriptors having constant value for all structures in the 
data set are also discarded; c) thereafter all possible one-parameter regression models are tested 
and insignificant descriptors are removed; d) the program calculates the pair correlation matrix 
of descriptors and further reduces the descriptor pool by eliminating highly correlated 
descriptors. Therefore, HM represents an excellent tool for descriptor selection in preliminary 
analysis of structural features affecting the activity of drugs.5 For the purpose of heuristic 
analysis in this work, whole set of 25 compounds was divided in two subsets: subset 1, 
composed of compounds without substituent at position 1 (1a-1l), and subset 2, containing 
compounds with phenyl ring at position 1 of pyrazol-5-one (1m-1y). We first performed one-
parameter heuristic analysis in order to investigate the structural features that are most significant 
for antiproliferative activity of compounds synthesized. Heuristic analysis of the most significant 
descriptors was applied on whole set, subset 1 and subset 2, regarding to activity on MDA-MB-
361 and MDA-MB-453 cancer cells.   
1.5. Flow cytometry analysis 
 
Cellular DNA content and cell distribution were quantified by flow cytometry using propidium 
iodide (PI). Cells (3 × 105 cells/well) were seeded in 6-well plates and incubated with or without 
2xIC50 concentration of investigated compounds for 24 h. After treatment, the cells were 
collected by trypsinization, and fixed in ice-cold 70% ethanol at -20ºC overnight. After fixation, 
the cells were washed in PBS and pellets obtained by centrifugation was treated with RNase (100 
lg/mL) at 37ºC temperature for 30 min and then incubated with propidium iodide (PI) (40 lg/mL) 
for at least 30 min. DNA content and cell cycle distribution were analyzed using a Becton 
Dickinson FAC-Scan flow cytometer. Flow cytometry analysis was performed using a 
CellQuestR (Becton Dickinson, San Jose, CA, USA), on a minimum of 10,000 cells per sample.6   
 
1.6. Tube formation assay (in vitro angiogenesis assay) 
Potential of investigated pyrazolones to inhibit angiogenesis in vitro was analyzed by tube 
formation assay in mouse endothelial cells (MS1-murineendothelialcells immortalized by 
infection encoding SV40 large T antigen). MS1 cells plated into gel of basement membrane 
proteins, rapidly organize into multicellular tube-like structures (R), while anti-angigenic effect 
of tested compounds is observed as reduction of tube formation.7 Briefly, 24-well plates were 
coated with collagen and allowed to solidify at 37°C 1 h.  
MS1 cells were seeded 1x105 cells/well in medium. 2 h after cells settled treatment was added. 
Compounds were applied in sub-toxic concentration being 30 µM (for group of compounds 1c, 
1d, 1g, 1h, 1i, 1k, 1l, 1x), 10 µM (for group of compounds 1b, 1e, 1f, 1j, 1p, 1y, 1v) and 3 µM 
(for group of compounds 1r, 1s, 1m, 1o, 1n, 1q, 1a, 1w, 1t, 1u), separated according to their 
cytotoxic potential. Tube formation was observed periodically over the time under microscope 
and representative pictures were taken after 12 h incubation. 
 
2. Antiproliferative activity 
  Fig. S1. and Fig. S2. depict the cytotoxic curves from MTT assay showing the survival of 
MDA-MB-361 and MDA-MB-453 cell grown for 72 h in the presence of increasing 
concentrations of 1o and 1q, respectively. 
 
 
Fig. S1. Representative graph shows survival of MDA-MB-361 cell grown for 72 h in the 
presence of increasing concentrations of 1o. 
 
 Fig. S2. Representative graph shows survival of MDA-MB-453 cell grown for 72 h in the 
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